SINGAPORE -- Future sales of COVID-19 vaccines will take place in "an annual vaccination market, a lot like influenza," according to Novavax's executive vice president.
The U.S.-based biotechnology company, which gained U.S. authorization for its vaccine last summer, produces its jabs in partnerships with companies such as the Serum Institute of India, the world's largest vaccine maker, and Japan's Takeda Pharmaceutical.
